Evidence map›Paper›PMID 40720020›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

In Vivo Evaluation of Dystrophin Exon Skipping in mdx Mice.

Bo Wu, Qi Long Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bo WuMcColl-Lockwood Laboratory for Muscular Dystrophy Research, Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA.
Qi Long LuMcColl-Lockwood Laboratory for Muscular Dystrophy Research, Musculoskeletal Institute, Atrium Health, Charlotte, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exon skipping of dystrophin in mdx mice has been the key model for the development of antisense therapy in vivo. Evaluation of exon skipping in this model involves the following two aspects: (1) efficiency and accuracy of exon skipping and levels of dystrophin expression determined by RT-PCR, immunochemistry and western blotting; (2) therapeutic effects on muscle pathology and functions assessed by histology and functional assays including grip strength measurement, treadmill exhaustion test, plethysmography for respiratory functional analysis and echocardiogram and hemodynamics for cardiac functions. Here we describe some key consideration and the essential methodologies in detail for exon skipping in mdx mice.

Indexed as

DystrophinExonsMuscular Dystrophy, DuchenneAnimalsDisease Models, AnimalMiceMice, Inbred mdxMuscle, SkeletalOligonucleotides, AntisenseDystrophinOligonucleotides, AntisenseDystrophinEchocardiogramExon skippingGrip strengthHemodynamicsImmunochemistryPlethysmographyRT-PCRTreadmillWestern blotting

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.